Candel Therapeutics (CADL) EBIT: 2020-2024
Historic EBIT for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$33.4 million.
- Candel Therapeutics' EBIT fell 27.37% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$33.4 million for FY2024, which is 13.08% up from last year.
- Candel Therapeutics' EBIT amounted to -$33.4 million in FY2024, which was up 13.08% from -$38.4 million recorded in FY2023.
- Over the past 5 years, Candel Therapeutics' EBIT peaked at -$13.8 million during FY2020, and registered a low of -$38.4 million during FY2023.
- For the 3-year period, Candel Therapeutics' EBIT averaged around -$35.5 million, with its median value being -$34.7 million (2022).
- In the last 5 years, Candel Therapeutics' EBIT crashed by 86.29% in 2021 and then rose by 13.08% in 2024.
- Over the past 5 years, Candel Therapeutics' EBIT (Yearly) stood at -$13.8 million in 2020, then tumbled by 86.29% to -$25.7 million in 2021, then tumbled by 34.97% to -$34.7 million in 2022, then decreased by 10.57% to -$38.4 million in 2023, then grew by 13.08% to -$33.4 million in 2024.